Top 30 Laboratory Geneticist Interview Questions and Answers [Updated 2025]

During a routine quality check, I noticed discrepancies in the Sanger sequencing results that indicated potential sample contamination. I immediately informed my supervisor and initiated a root cause analysis. Together, we retraced our steps and found that one of the reagents was improperly stored. We corrected the storage issue and repeated the sequencing, which resolved the problem. This experience reinforced my attention to detail and the importance of quality control in genetic testing.

During my Master's program, I worked on a team researching the genetic basis of a rare disease. I was responsible for data analysis, using bioinformatics tools to interpret sequencing data. We faced challenges in aligning large datasets, but by collaborating and sharing insights, we improved our methods. Our results contributed to a better understanding of the disease and were published in a peer-reviewed journal.

In a previous role, I faced an ethical dilemma when I discovered that a colleague was not following proper consent procedures for genetic testing. I approached my supervisor to discuss the matter, highlighting the potential harm to patients. We conducted a review and retrained the staff on consent protocols, ensuring patient rights were respected. This experience reinforced my belief in the importance of ethical guidelines in our work.

In my previous role, we updated our genetic testing protocol from Sanger sequencing to next-generation sequencing. I attended training sessions and quickly adapted by practicing the new methods in the lab. As a result, our turnaround time for results improved by 30%. This experience reinforced the importance of being proactive in learning new technologies.

In my previous role at XYZ Lab, I led a team of 4 in a critical project to develop a new assay for genetic variants. We faced a significant challenge when initial results were inconsistent. I organized daily check-ins to boost morale and identify issues quickly. We revised our protocols based on feedback, which led to a successful assay within two weeks. This accomplishment increased our lab's efficiency by 30%. I learned the importance of adaptive leadership.

In a recent test, I noticed that a sample was mislabelled. I double-checked the patient information and found that the order was mixed up. I corrected it before proceeding, preventing a misdiagnosis which could have led to wrong treatment for the patient.

During a project on SNP analysis, I disagreed with my colleague about the interpretation of the results. I suggested we hold a meeting to discuss our perspectives. We reviewed the data together and found that a different statistical approach clarified our disagreement. Ultimately, we combined our techniques, which improved our final report.

In my previous position, our turnaround time for genetic test results was too slow. I introduced a barcoding system for sample tracking which reduced errors and expedited processing. This innovation cut our turnaround time by 30%, ensuring quicker results for patients.

In my previous role, I noticed long wait times for PCR results due to inefficient sample processing. I proposed a new workflow that organized samples by priority and automated part of the data entry. This reduced processing time by 25%, allowing us to deliver results faster to clinicians.

I mentored a graduate student on a research project involving CRISPR technology. I guided her through the experimental design and helped her interpret the results. She became confident in her skills and presented our work at a conference, receiving great feedback.

The steps I take include preparing the DNA samples, conducting sequencing on an Illumina platform, performing quality control to filter out low-quality reads, aligning the data to a reference genome, and analyzing the variants for clinical significance.

I often use tools like GATK for variant calling and BLAST for sequence alignment. In a recent project analyzing genomic data from cancer patients, I utilized GATK to identify mutations. This led to valuable insights into potential treatment options based on the variants found.

PCR, or Polymerase Chain Reaction, is used for amplifying DNA, typically to generate large quantities from a small sample. qPCR, or quantitative PCR, builds on this by allowing for quantification of the DNA as it amplifies in real-time, which is useful in diagnostic assays. RT-PCR, or Reverse Transcription PCR, is specifically for converting RNA into DNA and then amplifying it, often used in gene expression studies.

I follow the ACMG guidelines for classification and utilize databases like ClinVar to check variant significance. I assess variant impact using predictive tools and always consider clinical context and family history to ensure accurate interpretations.

One significant advancement is CRISPR-Cas9 technology. It has revolutionized gene editing due to its precision and efficiency. This is crucial for correcting genetic disorders, which could change the lives of many patients.

I subscribe to key journals like Nature Genetics and regularly attend webinars to stay current.

CRISPR-Cas9 is a groundbreaking gene editing tool that allows scientists to modify DNA with precision. It works by using a guide RNA to direct the Cas9 enzyme to a specific location in the genome, where it makes a cut. This can lead to gene knockouts or modifications. It's widely used in research for creating genetically modified organisms and is also being explored for treating genetic disorders.

One challenge is ensuring precise delivery of gene therapies to the correct cells, as off-target effects can lead to complications. Additionally, the regulatory landscape is complex, requiring rigorous clinical trials before therapies can be publicly available.

Cytogenetics is the study of chromosomes and their role in genetics. It is crucial for detecting chromosomal abnormalities, such as aneuploidies, which can lead to conditions like Down syndrome. Techniques such as karyotyping and FISH are commonly used in diagnostics. In personalized medicine, cytogenetics helps tailor treatments based on genetic profiles, particularly in cancer.

Epigenetic modifications, such as DNA methylation and histone acetylation, can drastically influence gene expression by altering chromatin structure, making genes more or less accessible for transcription. Techniques like ChIP-seq are used to study protein-DNA interactions, while bisulfite sequencing helps analyze methylation patterns. For example, during differentiation, these modifications play key roles in ensuring genes for specific cell types are expressed while others are silenced.

I would first examine the patient's medical history to understand the context of the results. Then, I would research similar cases in the literature to see if there are precedents for interpreting these findings. Additionally, I'd use bioinformatics tools to gain insights and collaborate with team members to discuss the findings and consider follow-up tests if needed.

I would begin by saying, 'I understand that waiting for these results can be very stressful, and it's completely normal to feel anxious.' Then, I would explain the results using straightforward terms, like 'The test shows that there is a mutation that might increase risks for certain conditions, but we can talk about what this means for your health moving forward.' I would make sure they know they can ask any questions and that I'm here to support them.

I would first evaluate the root causes of the delay by meeting with team members. Once I understand the issues, I would prioritize the tasks that are crucial for progress, set new deadlines, and communicate these changes clearly to the team. Additionally, I would schedule regular updates to ensure we remain on track.

First, I would assess the extent of the contamination by examining all affected samples. Then, I would isolate those samples to prevent any further contamination. Next, I would thoroughly document my findings and the steps I took. After that, I would notify my supervisor and any relevant team members, ensuring everyone is aware. Finally, I would follow our standard operating procedures for handling contaminated samples to ensure safety.

I would set up weekly check-ins with the bioinformatics team to ensure we're aligned on our goals and can address any issues quickly.

I would start by clearly defining the project's critical goals. Then, I would assess which resources we have and what is currently being used. I would prioritize tasks based on their urgency and potential impact, ensuring that we focus on what will drive the project forward effectively. Lastly, I would communicate with the team to gather insights on their resource needs and adjust allocations accordingly.

First, I would review what specific genetic testing procedures were not documented. Then, I would reach out to colleagues who were involved in those tests to obtain the necessary details. I would document the information accurately and update the report accordingly. Lastly, I would suggest a meeting to address documentation standards to prevent this from happening in the future.

I recognize that genetic privacy is a crucial concern in our field. In this study, we are committed to anonymizing all genetic data and ensuring that no identifiable information is shared. We obtain informed consent from participants, explaining how their data will be used, and we adhere to all institutional ethical guidelines.

First, I would carefully review the assay procedure to confirm each step was correctly executed. Then, I would inspect the reagents for quality and expiry. If results are still unexpected, I would repeat the assay with a control sample to see if the issue persists.

I simplify complex genetic concepts using analogies relevant to their fields, ensuring everyone understands the importance of genetic data in our projects.